5. 進行性核上性麻痺 Progressive supranuclear palsy Clinical trials / Disease details

臨床試験数 : 89 / 薬物数 : 107 - (DrugBank : 40) / 標的遺伝子数 : 65 - 標的パスウェイ数 : 108

diseases per page:

Showing 1 to 10 of 89 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05187546 (ClinicalTrials.gov)	March 10, 2022	23/11/2021	Test-retest Study With [18F]PI-2620 in PSP-RS and NDC	An Open Label, Single Center Study to Evaluate the Safety and Test-retest Characteristics of [18F]PI ...	Progressive Supranuclear Palsy	Drug: [18F]-PI2620	Life Molecular Imaging GmbH	NULL	Recruiting	50 Years	80 Years	All	15	Phase 1	Germany
2	NCT03446807 (ClinicalTrials.gov)	December 2021	20/2/2018	Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism	Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism	Parkinson Disease;Multiple System Atrophy;Progressive Supranuclear Palsy	Drug: Droxidopa;Drug: Placebo Oral Tablet	Loma Linda University	H. Lundbeck A/S	Not yet recruiting	50 Years	N/A	All	32	Phase 2	United States
3	NCT04937530 (ClinicalTrials.gov)	June 23, 2021	16/6/2021	RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY	A Randomized, Double-blind, Controlled, Phase 2 Study to Assess Efficacy, Long Term Safety and Toler ...	Progressive Supranuclear Palsy	Drug: RT001;Drug: Placebo	Retrotope, Inc.	NULL	Recruiting	40 Years	80 Years	All	40	Phase 2	Germany
4	EUCTR2020-003911-90-PL (EUCTR)	07/05/2021	20/04/2021	A RANDOMIZED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY TO ASSESS EFFICACY, LONG TERM SAFETY AND TOLER ...	A RANDOMIZED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY TO ASSESS EFFICACY, LONG TERM SAFETY AND TOLER ...	Progressive supranuclear palsy(PSP) MedDRA version: 21.1;Level: PT;Classification code 10036813;Term ...	Product Name: RT001 Product Code: RT001 INN or Proposed INN: not assigned Other descriptive name: 9-CIS ...	Retrotope, Inc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	40	Phase 2	Hungary;Slovakia;Poland;Germany
5	EUCTR2020-003911-90-DE (EUCTR)	31/03/2021	30/11/2020	A RANDOMIZED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY TO ASSESS EFFICACY, LONG TERM SAFETY AND TOLER ...	A RANDOMIZED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY TO ASSESS EFFICACY, LONG TERM SAFETY AND TOLER ...	Progressive supranuclear palsy(PSP) MedDRA version: 21.1;Level: PT;Classification code 10036813;Term ...	Product Name: RT001 Product Code: RT001 INN or Proposed INN: not assigned Other descriptive name: 9-CIS ...	Retrotope, Inc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	50	Phase 2	Hungary;Slovakia;Poland;Germany
6	EUCTR2020-003911-90-SK (EUCTR)	23/03/2021	13/01/2021	A study to learn how well the drug RT001 works and how safe RT001 is in people who have progressive ...	A RANDOMIZED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY TO ASSESS EFFICACY, LONG TERM SAFETY AND TOLER ...	Progressive supranuclear palsy(PSP) MedDRA version: 21.1;Level: PT;Classification code 10036813;Term ...	Product Name: RT001 Product Code: RT001 INN or Proposed INN: not assigned Other descriptive name: 9-CIS ...	Retrotope, Inc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	40	Phase 2	Hungary;Slovakia;Poland;Germany
7	EUCTR2020-003911-90-HU (EUCTR)	19/02/2021	09/12/2020	A RANDOMIZED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY TO ASSESS EFFICACY, LONG TERM SAFETY AND TOLER ...	A RANDOMIZED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY TO ASSESS EFFICACY, LONG TERM SAFETY AND TOLER ...	Progressive supranuclear palsy(PSP) MedDRA version: 21.1;Level: PT;Classification code 10036813;Term ...	Product Name: RT001 Product Code: RT001 INN or Proposed INN: not assigned Other descriptive name: 9-CIS ...	Retrotope, Inc	NULL	Not Recruiting			Female: yes Male: yes	50	Phase 2	Hungary;Slovakia;Poland;Germany
8	NCT04539041 (ClinicalTrials.gov)	February 16, 2021	25/8/2020	Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supra ...	A Randomized, Participant, Investigator and Sponsor Blinded, Placebo-Controlled Study to Evaluate th ...	Progressive Supranuclear Palsy (PSP)	Drug: antisense oligonucleotide;Drug: placebo	Novartis Pharmaceuticals	NULL	Recruiting	40 Years	75 Years	All	66	Phase 1	United States;Canada;Germany;United Kingdom
9	NCT04734379 (ClinicalTrials.gov)	January 22, 2021	18/1/2021	Rho Kinase (ROCK) Inhibitor in Tauopathies - 1	A Phase 2a Open-Label Preliminary Safety, Tolerability, and Biomarker Study of Oral Fasudil in Patie ...	Progressive Supranuclear Palsy;Corticobasal Syndrome	Drug: Fasudil	Woolsey Pharmaceuticals	NULL	Active, not recruiting	35 Years	80 Years	All	15	Phase 2	United States
10	NCT04253132 (ClinicalTrials.gov)	January 1, 2021	17/12/2019	Evaluation of Tolfenamic Acid in Individuals With PSP at 12-Weeks	A Phase 2a Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ...	Progressive Supranuclear Palsy	Drug: Tolfenamic Acid;Drug: Placebos	NeuroTau, Inc.	The Cleveland Clinic	Not yet recruiting	40 Years	85 Years	All	24	Phase 1/Phase 2	United States

First Previous1 2 3 4 5…9Next Last